biote Corp
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
BTMD$1.08-2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands) (Unaudited)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Activities | ||
| Net loss | $(5,810) | $(21,430) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 750 | 538 |
| Bad debt expense | 161 | 30 |
| Amortization of debt issuance costs | 202 | 195 |
| Provision for obsolete inventory | 70 | — |
| Non-cash lease expense | 80 | 69 |
| Shares issued in settlement of litigation | — | 1,199 |
| Share-based compensation expense | 1,763 | 2,170 |
| (Gain) loss from change in fair value of warrant liability | — | 1,618 |
| Loss from change in fair value of earnout liability | 12,089 | 25,410 |
| Deferred income taxes | — | 103 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,329) | (728) |
| Inventory | 75 | 1,560 |
| Other current assets | 619 | 1,238 |
| Accounts payable | (109) | 857 |
| Deferred revenue | (22) | 205 |
| Accrued expenses | (1,094) | (22) |
| Operating lease liabilities | (73) | (20) |
| Net cash provided by operating activities | 7,372 | 12,992 |
| Investing Activities | ||
| Purchases of property and equipment | (704) | (62) |
| Purchases of capitalized software | (350) | (318) |
| Acquisitions, net of cash acquired | (11,122) | — |
| Net cash used in investing activities | (12,176) | (380) |
| Financing Activities | ||
| Repurchases of common stock | (4,088) | — |
| Principal repayments on term loan | (1,562) | (1,562) |
| Proceeds from exercise of stock options | 324 | 420 |
| Distributions | (83) | (3,093) |
| Net cash used in financing activities | (5,409) | (4,235) |
| Effect of exchange rate changes on cash and cash equivalents | (2) | — |
| Net increase (decrease) in cash and cash equivalents | (10,215) | 8,377 |
| Cash and cash equivalents at beginning of period | 89,002 | 79,231 |
| Cash and cash equivalents at end of period | $78,787 | $87,608 |
| Supplemental Disclosure of Cash Flow Information | ||
| Cash paid for interest | $2,230 | $2,230 |
| Cash paid for income taxes | $2 | $2,232 |
| Non-cash investing and financing activities | ||
| Capital expenditures and capitalized software included in accounts payable | $85 | $94 |
| Shares issued to acquire Simpatra | $1,574 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.